ELVN

Enliven Therapeutics, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 7

R&D expenses decreased by 17% YoY due to strategic pipeline pruning.

margin expansion

60%

neutralMay 7

Maintains a $200M ATM facility for future liquidity needs.

capital raise

40%

bullishMay 7

Ceased development of ELVN-002 to focus resources on the lead BCR-ABL program.

divestiture

70%

bullishMay 7

R&D expenses decreased by 17% YoY due to strategic pipeline pruning.

margin expansion

60%

neutralMay 7

Maintains a $200M ATM facility for future liquidity needs.

capital raise

40%

bullishMay 7

Ceased development of ELVN-002 to focus resources on the lead BCR-ABL program.

divestiture

70%

bullishMay 7

R&D expenses decreased by 17% YoY due to strategic pipeline pruning.

margin expansion

60%

neutralMay 7

Maintains a $200M ATM facility for future liquidity needs.

capital raise

40%

bullishMay 7

Ceased development of ELVN-002 to focus resources on the lead BCR-ABL program.

divestiture

70%

bullishMay 7

R&D expenses decreased by 17% YoY due to strategic pipeline pruning.

margin expansion

60%

neutralMay 7

Maintains a $200M ATM facility for future liquidity needs.

capital raise

40%

bullishMay 7

Ceased development of ELVN-002 to focus resources on the lead BCR-ABL program.

divestiture

70%

bullishMay 7

R&D expenses decreased by 17% YoY due to strategic pipeline pruning.

margin expansion

60%

neutralMay 7

Maintains a $200M ATM facility for future liquidity needs.

capital raise

40%

bullishMay 7

Ceased development of ELVN-002 to focus resources on the lead BCR-ABL program.

divestiture

70%

bullishMay 7

R&D expenses decreased by 17% YoY due to strategic pipeline pruning.

margin expansion

60%

neutralMay 7

Maintains a $200M ATM facility for future liquidity needs.

capital raise

40%

bullishMay 7

Ceased development of ELVN-002 to focus resources on the lead BCR-ABL program.

divestiture

70%

bullishMay 7

R&D expenses decreased by 17% YoY due to strategic pipeline pruning.

margin expansion

60%

neutralMay 7

Maintains a $200M ATM facility for future liquidity needs.

capital raise

40%

bullishMay 7

Ceased development of ELVN-002 to focus resources on the lead BCR-ABL program.

divestiture

70%

Filing History

10-QMay 7, 2026

The 10-Q reveals a company at a critical inflection point, balancing a pristine balance sheet against an aggressive clinical timeline. The strategic decision to cease development of ELVN-002 simplifies the investment thesis but concentrates all risk into the BCR-ABL program. While the financial metrics show a disciplined reduction in burn, the underlying reality is that Enliven is racing against its own cash clock to prove the efficacy of its lead asset. Ultimately, the impact of this filing is a narrowing of the risk-reward profile. The downside is mitigated by a massive cash cushion that prevents immediate insolvency, but the upside is now strictly tied to the success of ELVN-001. Investors are no longer betting on a platform of possibilities, but on the execution of a single, high-conviction clinical path.